Holen Sie sich die Stockscreener-App
2.40
2.56%
0.06
Schlusskurs vom Vortag:
$2.34
Offen:
$2.4
24-Stunden-Volumen:
213.28K
Relative Volume:
0.80
Marktkapitalisierung:
$244.26M
Einnahmen:
$4.60M
Nettoeinkommen (Verlust:
$-82.31M
KGV:
-2.9261
EPS:
-0.8202
Netto-Cashflow:
$-87.79M
1W Leistung:
+6.19%
1M Leistung:
-13.36%
6M Leistung:
-18.64%
1J Leistung:
+21.21%
1-Tages-Spanne:
$2.335
$2.425
1-Wochen-Bereich:
$2.25
$2.425
52-Wochen-Spanne:
$1.65
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.40 | 244.26M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis - TradingKey
AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACIU Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
June 2026 Penny Stocks To Watch For Potential Growth - simplywall.st
AC Immune (ACIU) director receives restricted share units and options grant - Stock Titan
AC Immune (ACIU) director receives new RSU and stock option grants - Stock Titan
AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options - Stock Titan
AC Immune (ACIU) grants RSUs and stock options to director Buetler - Stock Titan
[Form 4] AC Immune SA Insider Trading Activity - Stock Titan
AC Immune Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Investor ResponseDividend Increase Stocks - newsline.com
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM - TipRanks
AC Immune (NASDAQ: ACIU) AGM clears 2025 loss, extends capital band and boosts liquidity runway - Stock Titan
AC Immune receives $4m grant for Parkinson’s trial extension - Investing.com UK
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial - TipRanks
AC Immune receives $4m grant for Parkinson’s trial extension By Investing.com - Investing.com Canada
AC Immune (NASDAQ: ACIU) awarded $4M grant to extend ACI-7104 PD trial - Stock Titan
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease - GlobeNewswire
AC Immune Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift SentimentEPS Growth Report - newsline.com
ACIU: Precision prevention pipeline advances with strong clinical data and major pharma partnerships - TradingView
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesPreliminary Results - newsline.com
AC Immune Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue; Stock DeclinesRevenue Surprise History - newsline.com
ACIU Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesEarnings Growth Analysis - thelegaladvocate.com
ACIU PE Ratio & Valuation, Is ACIU Overvalued - Intellectia AI
ACIU Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline Progress ContinuesConsensus Beat Rate - The Legal Advocate
AC Immune CEO Andrea Pfeifer to retire after 23 years By Investing.com - Investing.com Nigeria
AC Immune (ACIU) Rallies Nearly 5% as Biotech Eyes Key Resistance BreakoutInstitutional Buy Signals - thelegaladvocate.com
AC Immune Q1 2026 Earnings: EPS Slightly Beats Estimates Amid Pre-Revenue StageEBITDA Margin Trends - The Legal Advocate
ACIU Q1 2026 Earnings: Narrower Net Loss Highlights Cost Discipline in Pre-Revenue PhaseEarnings Quality Analysis - newsline.com
AC Immune (ACIU) Reveals Promising Data on ALS PET Tracer - GuruFocus
AC Immune’s PET tracer shows uptake in ALS patients’ brains By Investing.com - Investing.com South Africa
AC Immune presents new Phase 1 data on uptake of ACI-19626 - TipRanks
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS - markets.businessinsider.com
AC Immune SA’s ACI-19626 PET Tracer Shows Increased Uptake in ALS Patients - geneonline.com
AC Immune Announces Phase 1 Results Showing Enhanced Uptake of TDP-43 PET Tracer ACI-19626 in ALS Patients at 2026 TDP43 Summit - Quiver Quantitative
AC Immune’s PET tracer shows uptake in ALS patients’ brains - Investing.com
AC Immune's experimental ALS brain scan visualizes TDP-43 buildup - Stock Titan
AC Immune Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesCommunity Hot Stocks - Newser
Top Executive Move at AC Immune SA Sparks Fresh Investor Buzz - TipRanks
10K-share sale by AC Immune (ACIU) CEO Andrea Pfeifer disclosed - Stock Titan
Co-founder and CEO steps down - European Biotechnology Magazine
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires - The Globe and Mail
Affiliate sells 20,000 shares — ACIU (NASDAQ: ACIU) reports Form 144 - Stock Titan
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):